• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

多发性骨髓瘤的个体化护理：探索治疗方案并满足患者需求。

Individualizing Care for Multiple Myeloma: Navigating Treatment Options and Addressing Patient Needs.

作者信息

Finley-Oliver Beth, Baz Rachid

机构信息

From H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.

出版信息

J Adv Pract Oncol. 2024 Apr;15(3):204-208. doi: 10.6004/jadpro.2024.15.3.10. Epub 2024 Apr 1.

DOI:10.6004/jadpro.2024.15.3.10
PMID:39297066
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11406320/
Abstract

At JADPRO Live 2023 in Orlando, presenters discussed selecting treatment regimens for newly diagnosed and relapsed or refractory multiple myeloma. They also provided insights on comprehensive care centered around patient preferences, treatment goals, side effect mitigation, and supportive care needs of patients with multiple myeloma.

摘要

在奥兰多举行的2023年JADPRO直播活动中，演讲者讨论了为新诊断以及复发或难治性多发性骨髓瘤选择治疗方案。他们还围绕患者偏好、治疗目标、减轻副作用以及多发性骨髓瘤患者的支持性护理需求，提供了关于综合护理的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f85a/11406320/842315a88728/jadpro-15-204-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f85a/11406320/842315a88728/jadpro-15-204-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f85a/11406320/842315a88728/jadpro-15-204-g001.jpg

相似文献

1
Individualizing Care for Multiple Myeloma: Navigating Treatment Options and Addressing Patient Needs.多发性骨髓瘤的个体化护理：探索治疗方案并满足患者需求。
J Adv Pract Oncol. 2024 Apr;15(3):204-208. doi: 10.6004/jadpro.2024.15.3.10. Epub 2024 Apr 1.
2
Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma.复发/难治性多发性骨髓瘤患者的新型治疗方法
J Adv Pract Oncol. 2023 Apr;14(3):252-256. doi: 10.6004/jadpro.2023.14.3.14. Epub 2023 Apr 1.
3
Improving Prostate Cancer Patient Care in the Clinical Setting.改善临床环境中前列腺癌患者的护理。
J Adv Pract Oncol. 2024 Apr;15(3):200-203. doi: 10.6004/jadpro.2024.15.3.9. Epub 2024 Apr 1.
4
Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者和医生在治疗选择中共同决策的调查。
Transl Behav Med. 2023 Apr 15;13(4):255-267. doi: 10.1093/tbm/ibac099.
5
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.达雷妥尤单抗用于初诊及复发/难治性多发性骨髓瘤的治疗：当前及新出现的疗法
Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.
6
Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients.新诊断多发性骨髓瘤患者最佳治疗方案的选择策略
Semin Oncol Nurs. 2017 Aug;33(3):254-264. doi: 10.1016/j.soncn.2017.05.003. Epub 2017 Jul 3.
7
Isatuximab for the treatment of relapsed/refractory multiple myeloma.依沙佐米单抗治疗复发/难治性多发性骨髓瘤。
Expert Opin Biol Ther. 2020 Dec;20(12):1395-1404. doi: 10.1080/14712598.2021.1841747.
8
Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany.患者对多发性骨髓瘤及其治疗的看法：来自英国、法国和德国患者访谈的定性证据。
Patient. 2021 Sep;14(5):613-623. doi: 10.1007/s40271-021-00501-7. Epub 2021 Mar 9.
9
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.接受idecabtagene vicleucel或标准方案治疗的三重暴露复发难治性多发性骨髓瘤患者的健康相关生活质量：3期随机开放标签KarMMa-3临床试验的患者报告结局
Lancet Haematol. 2024 Mar;11(3):e216-e227. doi: 10.1016/S2352-3026(24)00005-X.
10
Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.美国、英国、意大利、德国、法国和西班牙复发或难治性多发性骨髓瘤患者的治疗偏好：离散选择实验的结果
Front Med (Lausanne). 2023 Nov 23;10:1271657. doi: 10.3389/fmed.2023.1271657. eCollection 2023.